GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.